Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin^® to treat major depressive disorder (MDD). The randomized, double blind, and placebo-controlled study began enrollment in January 2011 and enrolled a total of 300 patients at approximately 40 sites in the United States. The Company expects to report preliminary findings from the trial in late 2011. The primary efficacy endpoint of the study is the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS).

“We look forward to completing the trial and announcing preliminary results before the end of the year.”

"We are very excited by the speed at which we've completed enrollment in our Phase IIb trial for Serdaxin and believe that this further validates the current unmet need for an effective treatment for major depressive disorder," said Rick Soni, President and Chief Operating Officer. "We look forward to completing the trial and announcing preliminary results before the end of the year."